Pharmacological regulation of chondrocyte ferroptosis by plant-derived metabolites in osteoarthritis: from molecular mechanisms to targeted nanodelivery
- 1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine , ,
Abstract
Osteoarthritis (OA) lacks approved disease-modifying pharmacotherapy. Chondrocyte ferroptosis—iron-dependent phospholipid peroxidation caused by disrupted iron handling, lipid metabolism, and antioxidant defense—has been implicated in cartilage degeneration and is pharmacologically suppressible in experimental models. Natural products can modulate multiple ferroptosis-related nodes, including the Nrf2/SLC7A11/GPX4 axis, ACSL4-dependent lipid peroxidation, iron homeostasis, and mitochondrial redox balance. Their translation, however, is limited by poor solubility, instability, rapid clearance, uncertain dose–exposure relationships, and restricted cartilage penetration. This review integrates the pharmacological basis of chondrocyte ferroptosis, evidence for anti-ferroptotic natural products, and nanodelivery strategies that improve joint retention, cartilage targeting, chondrocyte uptake, and controlled release. We distinguish direct ferroptosis evidence from adjacent antioxidant or chondroprotective findings and evaluate polymeric, lipid-based, hydrogel, biomimetic, inorganic, and hybrid platforms as pharmacological optimization tools. Current integrated systems show encouraging structure-preserving effects in experimental OA, but evidence remains predominantly preclinical. Translation will require standardized compounds, ferroptosis-specific target-engagement assays, pharmacokinetic and dose–response studies, carrier-specific safety testing, clinically relevant models, and biomarker-guided patient selection. Rationally matching natural-product pharmacology with joint-specific delivery may enable mechanism-based OA therapies.
Related
- Tacrolimus attenuates BCL-2/BAX-mediated chondrocyte apoptosis and cartilage matrix degradation in experimental osteoarthritis
- N-Acetylglucosamine ameliorates knee osteoarthritis by enhancing UDP-GlcNAc conversion and chondrocyte DNA repair capacity
- Immune–chondrocyte ligand–receptor axes in osteoarthritis: microenvironmental control of inflammation, matrix remodeling, and chondrocyte fate
- Isoquercitrin ameliorates chondrocyte dysfunction in osteoarthritis by targeting AKT1-mediated mitochondrial dynamics regulation
- Leptin promotes obesity‑related osteoarthritis progression via CD44/JAK2/STAT3 axis‑mediated chondrocyte apoptosis.
BibTeX
@article{guo2026pharmacological,
title = {{Pharmacological regulation of chondrocyte ferroptosis by plant-derived metabolites in osteoarthritis: from molecular mechanisms to targeted nanodelivery}},
author = {Tianci Guo and Qi Liu and Jida Wang and Keming Ren and Longyao Zhang and Jinzhong Sheng and Aifeng Liu},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1949976},
url = {https://europepmc.org/article/PMC/PMC13691434},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pharmacological regulation of chondrocyte ferroptosis by plant-derived metabolites in osteoarthritis: from molecular mechanisms to targeted nanodelivery
AU - Tianci Guo
AU - Qi Liu
AU - Jida Wang
AU - Keming Ren
AU - Longyao Zhang
AU - Jinzhong Sheng
AU - Aifeng Liu
PY - 2026
DA - 2026/10/09
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1949976
UR - https://europepmc.org/article/PMC/PMC13691434
AB - Osteoarthritis (OA) lacks approved disease-modifying pharmacotherapy. Chondrocyte ferroptosis—iron-dependent phospholipid peroxidation caused by disrupted iron handling, lipid metabolism, and antioxidant defense—has been implicated in cartilage degeneration and is pharmacologically suppressible in experimental models. Natural products can modulate multiple ferroptosis-related nodes, including the Nrf2/SLC7A11/GPX4 axis, ACSL4-dependent lipid peroxidation, iron homeostasis, and mitochondrial redox balance. Their translation, however, is limited by poor solubility, instability, rapid clearance, uncertain dose–exposure relationships, and restricted cartilage penetration. This review integrates the pharmacological basis of chondrocyte ferroptosis, evidence for anti-ferroptotic natural products, and nanodelivery strategies that improve joint retention, cartilage targeting, chondrocyte uptake, and controlled release. We distinguish direct ferroptosis evidence from adjacent antioxidant or chondroprotective findings and evaluate polymeric, lipid-based, hydrogel, biomimetic, inorganic, and hybrid platforms as pharmacological optimization tools. Current integrated systems show encouraging structure-preserving effects in experimental OA, but evidence remains predominantly preclinical. Translation will require standardized compounds, ferroptosis-specific target-engagement assays, pharmacokinetic and dose–response studies, carrier-specific safety testing, clinically relevant models, and biomarker-guided patient selection. Rationally matching natural-product pharmacology with joint-specific delivery may enable mechanism-based OA therapies.
SN - 1663-9812
ER -